Table 4 Drugs ordered according to the accuracy (MSE) of prediction
From: Deep learning and multi-omics approach to predict drug responses in cancer
MSE | Drug name | Putative target | Pathway name |
|---|---|---|---|
1.1 | LGK974 | PORCN | WNT signalling |
1.2 | EPZ004777 | DOT1L | Chromatin histone methylation |
1.4 | EPZ5676 | DOT1L | Chromatin histone methylation |
1.4 | GSK1904529A | IGF1R, IR | IGF1R signalling |
1.5 | MK-1775 | WEE1, PLK1 | Cell cycle |
2.1 | Palbociclib | CDK4, CDK6 | Cell cycle |
2.2 | Afatinib | ERBB2, EGFR | EGFR signalling |
2.3 | PD0325901 | MEK1, MEK2 | ERK MAPK signalling |
2.4 | Linsitinib | IGF1R | IGF1R signalling |
2.5 | Oxaliplatin | DNA alkylating agent | DNA replication |
2.6 | Sapatinib | EGFR, ERBB2, ERBB3 | EGFR signalling |
2.6 | PLX-4720 | BRAF | ERK MAPK signalling |
2.6 | Alpelisib | PI3Kalpha | PI3K/MTOR signalling |
2.7 | SCH772984 | ERK1, ERK2 | ERK MAPK signalling |
2.8 | MK-2206 | AKT1, AKT2 | PI3K/MTOR signalling |
2.8 | Nutlin-3a (-) | MDM2 | p53 pathway |
3.2 | 5-Fluorouracil | Antimetabolite (DNA & RNA) | Other |
3.7 | Taselisib | PI3K (beta sparing) | PI3K/MTOR signalling |
3.8 | Irinotecan | TOP1 | DNA replication |
4.0 | Luminespib | HSP90 | Protein stability and degradation |
4.1 | Trametinib | MEK1, MEK2 | ERK MAPK signalling |
4.8 | Camptothecin | TOP1 | DNA replication |